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BP Reduction, Kidney Function Decline, and
Cardiovascular Events in Patients without CKD
Rita Magric¸o,1 Miguel Bigotte Vieira,2 Catarina Viegas Dias,3 Lia Leita˜o,4 and Joa˜o Se´rgio Neves5,6
Abstract
Background and objectives In the Systolic Blood Pressure Intervention Trial (SPRINT), intensive systolic BP
treatment (target,120mmHg) was associated with fewer cardiovascular events and higher incidence of kidney
function decline comparedwith standard treatment (target,140mmHg).We evaluated the association between
mean arterial pressure reduction, kidney function decline, and cardiovascular events in patients without CKD.
Design, setting, participants, & measurements We categorized patients in the intensive treatment group of
the SPRINT according tomean arterial pressure reduction throughout follow-up:,20, 20 to,40, and$40mm
Hg. We deﬁned the primary outcome as kidney function decline ($30% reduction in eGFR to ,60 ml/min per
1.73 m2 on two consecutive determinations at 3-month intervals), and we deﬁned the secondary outcome as
cardiovascular events. In a propensity score analysis, patients in each mean arterial pressure reduction category
from the intensive treatment groupwerematchedwith patients from the standard treatment group to calculate the
numberneeded to treat regardingcardiovascular events andthenumberneeded toharmregardingkidney function
decline.
Results In the intensive treatment group, 1138 (34%) patients attained mean arterial pressure reduction,20 mm
Hg, 1857 (56%) attained 20 to ,40 mm Hg, and 309 (9%) attained $40 mm Hg. Adjusted hazard ratios for
kidney function decline were 2.10 (95% conﬁdence interval, 1.22 to 3.59) for mean arterial pressure reduction
between 20 and 40 mmHg and 6.22 (95% conﬁdence interval, 2.75 to 14.08) for mean arterial pressure reduction
$40 mm Hg. In propensity score analysis, mean arterial pressure reduction ,20 mm Hg presented a number
needed to treat of 44 and a number needed to harm of 65, reduction between 20 and ,40 mm Hg presented a
number needed to treat of 42 and a number needed to harm of 35, and reduction$40mmHg presented a number
needed to treat of 95 and a number needed to harm of 16.
Conclusions In the intensive treatment groupof SPRINT, larger declines inmean arterial pressurewere associated
with higher incidence of kidney function decline. Intensive treatment seemed to be less favorable when a larger
reduction in mean arterial pressure was needed to attain the BP target.
Clin J Am Soc Nephrol 13: 73–80, 2018. doi: https://doi.org/10.2215/CJN.05510517
Introduction
Hypertension is a major public health issue, and it is
expected to affect 1.56 billion people worldwide by
2025 (1). The Systolic Blood Pressure Intervention
Trial (SPRINT) was a multicenter, randomized, con-
trolled trial comparing intensive with standard sys-
tolic BP control (,120 versus,140 mmHg) in patients
without diabetes and with high cardiovascular risk.
It showed lower rates of fatal and nonfatal major cardio-
vascular events in the intensive treatment group. The trial
was stopped earlier (after 3.26 years of follow-up) due to a
signiﬁcantly lower rate of the primary outcome in the
intensive treatment group.
However, in patients without prior kidney disease,
intensive treatment was associated with an higher
incidence of kidney function decline deﬁned by a
$30% reduction in eGFR to ,60 ml/min per 1.73 m2
on two consecutive laboratory determinations col-
lected at 3-month intervals (hazard ratio, 3.49; 95%
conﬁdence interval [95% CI], 2.44 to 5.10; P value
,0.001) (2). This ﬁnding was unexpected, because
hypertension control was thought to be associated
with a lower rate of kidney function decline (3,4).
We hypothesize that a greater difference between
the baseline mean arterial pressure (MAP) and the
lowest attained MAP may be associated with a higher
risk of kidney function decline. We aimed to test
whether there was an association between the mag-
nitude of MAP reduction and the incidence of kidney
function decline in the intensive treatment group of
the SPRINT.
Materials and Methods
We performed a secondary data analysis of the
SPRINT database using the dataset that was released
with the SPRINT Data Analysis Challenge (5). The
SPRINT was a multicenter, randomized, controlled
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trial that included 9361 patients with an age of at least 50
years old, a systolic BP of 130–180 mm Hg, and high risk of
cardiovascular events. Patients with diabetes mellitus or
prior stroke were excluded (2). Detailed inclusion and
exclusion criteria are listed in the supplementary appendix
of the SPRINT (3). The study was conducted in accordance
with Good Clinical Practice, all applicable subject privacy
requirements, and the guiding principles of Helsinki.
We submitted our protocol to the ethics committee of
one author’s institution (Hospital Garcia de Orta) and re-
ceived an exemption certiﬁcate according to the application
rules of the National Heart, Lung, and Blood Institute data
repository.
We analyzed patients without prior CKD, deﬁned as
eGFR,60 ml/min per 1.73 m2, in the intensive treatment
group and excluded those without any BP measurements
during follow-up or lacking baseline eGFR values.
MAP was calculated for each patient (one third of the
systolic BP value plus two thirds of the diastolic BP value).
We created a new variable (MAP reduction) corresponding
to the difference between baseline MAP and minimum
MAP achieved throughout follow-up. We categorized
patients according to MAP reduction as ,20, 20 to ,40,
and $40 mm Hg.
Primary outcome was kidney function decline as deﬁned
in the SPRINT protocol (3): a $30% reduction in eGFR to
,60 ml/min per 1.73 m2 on two consecutive laboratory
determinations collected at 3-month intervals. Secondary
outcome was the occurrence of cardiovascular events as
deﬁned in the primary composite outcome of the SPRINT
(myocardial infarction, acute coronary syndrome not result-
ing in myocardial infarction, stroke, acute decompensated
heart failure, and mortality from cardiovascular causes).
To assess the crude association between MAP reduction
and primary and secondary outcomes, we performed
Kaplan–Meier curve and log rank tests. We performed a
Cox proportional hazards model adjusted for the following
potential confounders: age, sex, black race, smoking status,
cardiovascular disease (clinical or subclinical), number of
antihypertensive agents, statin and aspirin use, ratio of
urinary albumin to creatinine, and baseline MAP. A test for
trend over categories of MAP reduction was performed
where each category median was modeled as a continuous
variable in the regression model. Additionally, we also
performed the Cox proportional hazards models using
MAP reduction as a continuous variable. The proportional
hazards assumption was tested, and there was no evidence
of violation.
We also performed a supplementary analysis including a
Cox proportional hazards model analysis adjusted for the
same confounders but categorizing patients according to a
20-mm Hg cutoff of systolic BP and diastolic BP reduction
and a 5-mmHg cutoff of MAP, systolic BP, and diastolic BP
reduction. We performed the same analysis according to
MAP, systolic BP, and diastolic BP tertiles.
We then analyzed the group of patients in each category
of MAP reduction in the intensive treatment group,
matching them to patients in the standard treatment group
with similar baseline characteristics. We used a propensity
score, which included the following baseline covariates:
age, sex, black race, smoking status, cardiovascular disease
(clinical or subclinical), number of antihypertensive agents,
statin and aspirin use, ratio of urinary albumin to creat-
inine, systolic BP, diastolic BP, eGFR, glucose, total cho-
lesterol, HDL, and triglycerides. We calculated the number
needed to treat (NNT) over the course of the trial consid-
ering the absolute risk reduction of cardiovascular events
between matched groups and the number needed to harm
(NNH) considering the absolute risk increase of kidney
function decline in matched groups.
We also evaluated the association between kidney func-
tion decline and cardiovascular events and the effect
modiﬁcation by treatment group. For this analysis, we
used a Cox proportional hazards model with cardiovas-
cular events as outcome and assessed the interaction
between intensive treatment and kidney function decline
with a likelihood ratio test for the interaction.
Because the degree of missing data was low (described in
Results below), patients with missing values in any one of
the variables of the adjusted Cox proportional hazards
model or the propensity score model were excluded. For
those participants lost to follow-up, we used all available
information until the time of last assessment.
Continuous variables are presented as means6SD when
normally distributed or medians (25th percentiles to 75th
percentiles) when not normally distributed. Categorical
variables are presented as percentages. A two-sided P value
of ,0.05 was considered statistically signiﬁcant. Stata/IC
14.1 was used.
Results
We included 3304 patients in our analysis of the intensive
treatment group after excluding 1332 with previous CKD,
34 without any value of BP during follow-up, and eight
patients without baseline eGFR. The average follow-up
was 3.25 years, with a total of 10,714 person-years of
follow-up. Missing data were present in only four of the
analyzed variables. Body mass index was missing in 20
(0.6%) patients, ratio of urinary albumin to creatinine was
missing in 157 (5%) patients, statin use was missing in 17
(0.5%) patients, and aspirin use was missing in nine (0.3%)
patients. Because of missing data in at least one of these
four variables, 180 (5.4%) patients were excluded from the
adjusted analysis, which included a total of 3124 patients.
Mean baseline MAP was 100611 mm Hg. The distribu-
tion of patients according to MAP reduction categories was
as follows: 1138 (34%) patients attained ,20 mm Hg, 1857
(56%) patients attained 20 to ,40 mm Hg, and 309 (9%)
patients attained $40 mm Hg. There were signiﬁcant differ-
ences among these groups (Table 1): patients with higher
MAP reduction were younger, had higher baseline BP
(MAP, systolic, and diastolic), and had higher values of
urinary albumin-to-creatinine ratio, total cholesterol, and HDL.
This group also had a higher proportion of current smokers.
Regardingmedications, these patientswere taking signiﬁcantly
fewer antihypertensive agents, statins, and aspirin.
The average value of the minimumMAP achieved in each
group was 7868 mm Hg for patients with MAP reduction
,20 mm Hg, 7467 mm Hg for those with MAP reduction
between 20 and ,40 mm Hg, and 6968 mm Hg for patients
with MAP reduction $40 mm Hg. MAP, systolic BP, and
diastolic BP in the three categories of MAP reduction over the
course of the trial are presented in Figure 1.
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In the analyzed population, the incidence rates of kid-
ney function decline among the different subgroups of MAP
reduction were as follows: 23 (2%) events for MAP reduction
of,20 mmHg, 77 (4%) events between 20 and,40 mmHg,
and 27 (9%) events for $40 mm Hg.
In the unadjusted analysis (Figure 2), the magnitude of
MAP reduction was signiﬁcantly associated with kidney
function decline (P value ,0.001). Compared with the
group of MAP reduction ,20 mm Hg, unadjusted hazard
ratios for kidney function decline were 1.94 (95% CI, 1.22 to
Table 1. Baseline characteristics of the study participants according to achieved mean arterial pressure reduction: <20, 20 to <40, and
‡40 mm Hg
Variables
Mean Arterial Pressure Reduction
,20 mm Hg, n=1138 20 to ,40 mm Hg, n=1857 $40 mm Hg, n=309
Age, yr 6769 6769 6369
Cardiovascular disease, % 19 18 21
Clinical 16 14 18
Subclinical 5 5 5
Women, % 33 34 37
Black race, % 35 31 40
Baseline BP, mm Hg
Systolic 128612 143612 163614.8
Diastolic 72610 8169 94611
Mean 9168 10268 117610
No. of antihypertensive agents 1.861.0 1.761.0 1.661.1
Body mass index, kg/m2 30.065.7 30.165.7 30.466.6
Serum creatinine, mg/dl 0.9460.17 0.9260.17 0.9360.19
eGFR, ml/min per 1.73 m2 81615 81616 83617
Urinary albumin to creatinine, mg/g 7.6 (5.1–14.8) 8.9 (5.6–17.6) 12.5 (7.7–27.0)
Fasting total cholesterol, mg/dl 188642 192640 204647
Fasting HDL cholesterol, mg/dl 52613 53614 55616
Fasting total triglycerides, mg/dl 103 (74–140) 107 (76–150) 110 (77–168)
Fasting plasma glucose, mg/dl 99614 99613 99617
Statin use, % 41 41 31
Aspirin use, % 51 50 44
Smoking status, %
Never smoked 42 44 43
Current smoker 16 14 25
Former smoker 42 42 33
Baseline characteristics of 3304 Systolic Blood Pressure Intervention Trial participantswithout CKDat baseline assigned to intensive BP
treatment according to achieved mean arterial pressure reduction. Values are percentages for categorical covariates, means6SD for
continuous covariates, or medians (interquartile ranges) where appropriate.
Figure1. | In the3304SPRINTparticipantswithoutCKDatbaselineassigned to intensiveBP treatment,meanarterial pressure (MAP), systolic
BP, and diastolic BP decreased in a rapid and sustained way, and participants attained similar values in the three categories of MAP reduction.
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3.10) for MAP reduction between 20 and ,40 mm Hg and
4.19 (95% CI, 2.40 to 7.30) for MAP reduction $40 mm Hg
(Supplemental Table 1). This association remained signiﬁ-
cant after multivariable analysis.
The covariates included in the multivariable analysis are
described inMaterials andMethods above. Compared with
the group of MAP reduction ,20 mm Hg, adjusted hazard
ratios for kidney function decline were 2.10 (95% CI, 1.22 to
3.59) for MAP reduction between 20 and ,40 mm Hg and
6.22 (95% CI, 2.75 to 14.08) for MAP reduction$40 mmHg.
Age (P=0.04) and ratio of urinary albumin to creatinine
(P=0.002) were also found to be independent predictors of
kidney function decline. Unadjusted and adjusted hazard
ratios for kidney function decline according to BP reduction
tertiles (MAP, systolic, and diastolic) and categories of BP
reduction (20- and 5-mm Hg cutoffs) in the intensive treatment
group are presented in Supplemental Tables 1–7.
The association with cardiovascular events was also
evaluated in the intensive treatment group. The incidence
rates of this outcome among the different subgroups of
MAP reduction were as follows: 61 (5%) events for MAP
reduction of ,20 mm Hg, 93 (5%) events between 20 and
,40 mm Hg, and 30 (10%) events for $40 mm Hg. The
unadjusted hazard ratios for cardiovascular events were
1.04 (95% CI, 0.71 to 1.52) for MAP reduction of 20 to
,40 mm Hg and 1.52 (95% CI, 0.87 to 2.64) for MAP
reduction of $40 mm Hg. The adjusted hazard ratios were
not statistically signiﬁcant: 0.93 (95% CI, 0.58 to 1.49) for
MAP reduction of 20 to ,40 mm Hg and 1.04 (95% CI, 0.47
to 2.31) for MAP reduction of $40 mm Hg.
The results of the continuous analysis were consistent
with the analysis of MAP reduction categories. The hazard
ratios for each 10-mm Hg of MAP reduction for kidney
function decline were 1.49 (95% CI, 1.32 to 1.69; P,0.001) in
the unadjusted analysis and 2.27 (95% CI, 1.77 to 2.90;
P,0.001) in the adjusted model. The hazard ratios for each
10-mm Hg MAP reduction for cardiovascular events were
1.12 (95% CI, 0.97 to 1.29; P=0.13) in the unadjusted
analysis and 0.99 (95% CI, 0.77 to 1.26; P=0.91) in the
adjusted model.
To assess the risk-beneﬁt balance of intensive treatment,
we compared the categories of patients without previous
CKDwith different magnitudes of MAP reduction (Table 2)
in the intensive treatment group (n=3084) with similar
patients in the standard treatment group (n=3084). The
MAP reductions were 1365 mm Hg in the intensive
treatment group with ,20 mm Hg of MAP reduction and
1068 mm Hg in the matched standard treatment group,
2866 mm Hg in the intensive treatment group with MAP
reduction between 20 and ,40 mm Hg and 19610 mm Hg
in the matched standard treatment group, and 4766 mm
Hg in the intensive treatment group with MAP reduction
.40 and 32611 mmHg in the matched standard treatment
group.
Considering the propensity score analysis, there were
22 (2.1%) kidney function decline events and 38 (3.6%)
cardiovascular events in the intensive treatment groupwith
,20 mm Hg of MAP reduction, and there were six (0.6%)
kidney function decline events and 62 (5.9%) cardiovascular
events in the respective standard treatment group. The
hazard ratio with intensive treatment for kidney function
decline was 3.83 (95% CI, 1.55 to 9.44; P=0.004), and the
hazard ratio with intensive treatment for cardiovascular
events was 0.63 (95% CI, 0.42 to 0.94; P=0.02).
In the intensive treatment group with MAP reduction
between 20 and ,40 mm Hg, there were 72 (4.1%) kidney
function decline events and 71 (4.1%) cardiovascular
events, and in the respective standard treatment group,
there were 22 (1.3%) kidney function decline events and 113
(6.5%) cardiovascular events. The hazard ratio with in-
tensive treatment for kidney function decline was 3.26 (95%
CI, 2.02 to 5.26; P,0.001), and the hazard ratio with
intensive treatment for cardiovascular events was 0.61
(95% CI, 0.45 to 0.82; P=0.02).
In the intensive treatment group with MAP reduction
.40 mm Hg, there were 26 (9.1%) kidney function decline
Figure 2. | A larger decrease inmean arterial pressure (MAP)was significantly associatedwith higher incidence of kidney function decline in
the 3304 SPRINT participants without CKD at baseline assigned to intensive BP treatment. Kidney function decline was defined by 30%
reduction in eGFR to ,60 ml/min per 1.73 m2 on two consecutive laboratory determinations collected at 3-month time intervals.
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events and 17 (5.9%) cardiovascular events, and in the
respective standard treatment group, there were eight (2.8%)
kidney function decline events and 20 (7.0%) cardiovascular
events. The hazard ratio with intensive treatment for kidney
function decline was 3.20 (95% CI, 1.45 to 7.07; P,0.04), and
the hazard ratio with intensive treatment for cardiovascular
events was 0.80 (95% CI, 0.42 to 1.53; P=0.50).
Considering the absolute risk described above, patients
with an MAP reduction of ,20 mm Hg presented an NNT
of 44 (absolute risk, 3.6% versus 5.9%) and an NNH of 65
(absolute risk, 2.1% versus 0.6%); patients with an MAP
reduction between 20 and ,40 mm Hg presented an NNT
of 42 (absolute risk, 4.1% versus 6.5%) and an NNH of 35
(absolute risk, 4.1% versus 1.3%), and patients with an
MAP reduction $40 mm Hg presented an NNT of 95
(absolute risk, 5.9% versus 7.0%) and an NNH of 16
(absolute risk, 9.1% versus 2.8%) (Figure 3).
Regarding the association between kidney function
decline and cardiovascular events, there was no signif-
icant heterogeneity by treatment group (P for interac-
tion =0.22), with a hazard ratio of 2.44 (95% CI, 1.01 to
5.94) in the standard treatment group and a hazard ratio
of 1.10 (95% CI, 0.48 to 2.49) in the intensive treatment
group (Figure 4).
Discussion
We found that, in patients without CKD, a larger
decrease in MAP was signiﬁcantly associated with higher
incidence of kidney function decline. Whereas the beneﬁt-
risk balance of intensive treatment became less favorable
with greater MAP reduction, the development of kidney
function decline did not seem to confer an increase in
cardiovascular risk.
Most clinical studies on BP control focus on systolic or
diastolic BP instead of MAP. However, many molecular
studies of kidney responses to hypertensive stimuli (such
as salt intake or volume expansion) use MAP to compare
the effect of the interventions being studied on BP (6,7). In
critical care patients, MAP is also preferred to systolic or
diastolic BP as a measure of kidney perfusion. Several
studies show an association between MAP reduction and
higher probability of kidney injury (8–10), but most of these
studies focus on increasing MAP to a minimum threshold
in hypotensive individuals. In general, autoregulation
guarantees GFR preservation for an MAP value between
80 and 180 mm Hg (11). However, the ability of the kidney
to adapt to BP changes is affected by physiologic and
pharmacologic factors. Patients with hypertension and
elderly patients are more prone to kidney arteriosclerosis,
and they are at higher risk for impaired autoregulation (12).
Because patients included in the SPRINT were older and
had high cardiovascular risk, they represent a population
of increased susceptibility to kidney hypoperfusion with
larger decreases in MAP.
BP reduction has been shown to be renoprotective when
it is associated with a decrease in intraglomerular pressure.
In those circumstances, the decrease in GFR is expected to
be,30%, to improve or resolve on repeated measurements,
and to be associated with a slower decline of GFR in the
long term (13). In the SPRINT, kidney function decline was
.30% and conﬁrmed on repeated measurements (2). Re-
garding eGFR decline slope, a secondary analysis of the
SPRINT by Cheung et al. (14) in patients with CKD found
that, although the rate of decline in eGFR in the intensive
treatment group and the standard treatment group was
low, the eGFR decline curve in the intensive treatment
group was actually steeper after the initial 6 months. It is
Figure3. | Thebalancebetweenbenefitsand risksbecomes less favorable asMAPreduction increases, as shownby thenumberneeded to treat
and the number needed to harm of participants assigned to intensive blood pressure control and propensity score–matched participants
assigned to standard blood pressure control, according to achievedmean arterial pressure reduction (<20mmHg; 20 to<40mmHg and‡40
mmHg). The following baseline covariateswere included: age, sex, black race, smoking status, cardiovascular disease (clinical or subclinical),
number of antihypertensive agents, statin and aspirin use, systolic BP, diastolic BP, estimated glomerular filtration rate, glucose, ratio of urinary
albumin to creatinine, total cholesterol, high-density lipoproteins, triglycerides. NNT, number needed to treat; NNH, number needed to harm;
MAP, mean arterial pressure; BP, blood pressure.
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possible that the decrease in eGFR that we detected
corresponds to a structural injury to the kidney caused
by a sustained decrease in effective arterial blood volume
after institution of antihypertensive agents and as such,
does not correspond to a renoprotective reduction in intra-
glomerular pressure. Previous studies in patients with CKD,
including a meta-analysis of 1.7 million patients, showed an
association between a 30% reduction in eGFR and a higher
long-term risk of ESRD (15,16). Thus, in our population,
kidney function decline may be detrimental in the long term.
However, this question needs to be examined in detail in this
population.
In our analysis, kidney function decline and cardiovas-
cular events were higher in both the intensive and matched
standard groups with greater MAP reductions. This ﬁnd-
ing may be explained by the fact that patients who attained
greater decrease in BP also presented higher baseline BP
and thus, might present higher cardiovascular (17) and
kidney injury risks (18). Although intensive treatment
decreases the risk of cardiovascular events across the
matched groups, it also greatly increases the risk of kidney
function decline. The balance between beneﬁts and risks
becomes less favorable as MAP reduction increases.
Furthermore, we evaluated the association between the
occurrence of kidney function decline and cardiovascular
events in both treatment groups. Although the hazard ratio
for cardiovascular events in the standard treatment group
was higher among patients with kidney function decline
compared with patients without kidney function decline,
the interaction between kidney function decline and treat-
ment group was nonsigniﬁcant. This analysis must be
interpreted as exploratory, because it was limited by the
low number of patients who developed both kidney
function decline and cardiovascular events over the course
of the study. Adequately powered conﬁrmatory studies
with a longer follow-up are needed to ascertain the true
effect of BP treatment–associated kidney function decline in
cardiovascular risk.
Regarding the strengths of our study, we performed a
secondary analysis of a large multicenter, randomized,
controlled trial, evaluating an unexpected ﬁnding of the
SPRINT. The deﬁnition used for kidney function decline
was prespeciﬁed in the SPRINT, requiring a 3-month
interval between two consecutive laboratory determina-
tions. Because CKD is a major known cardiovascular risk
factor (19,20), the identiﬁcation of patients more likely to
develop kidney function decline with intensive BP treat-
ment is clinically relevant.
Considering limitations of our study, longitudinal cre-
atinine values were not included in the SPRINT Data
Analysis Challenge dataset, thus not allowing the compar-
ison of eGFR decline rates between groups. Moreover, it is
possible that the higher incidence of kidney function
decline was due to the unbalanced distribution of cardio-
vascular risk among categories of MAP reduction. Indi-
viduals who had a greater MAP reduction had signiﬁcantly
higher BP at baseline (MAP, systolic, and diastolic), higher
total cholesterol, and higher ratio of urinary albumin to
creatinine. There was a higher proportion of current
smokers, and on average, these patients were taking a
smaller number of antihypertensive agents, statins, and
aspirin, possibly indicating that they received less medical
supervision before trial entry. However, we adjusted for
cardiovascular disease, and on the propensity score analysis,
we matched the individuals for all of the above-mentioned
variables. As in all secondary analyses, our study has an
exploratory nature, and patients were not originally
randomized for MAP reduction; therefore, it is possible
that residual confounding exists due to unmeasured vari-
ables. The relationship between beneﬁt and risk of intensive
BP lowering must be interpreted with caution. In patients
who are hypertensive with lower cardiovascular risk than
those included in the SPRINT, the beneﬁt of intensive BP
control and the risk of developing kidney function decline
may be different (21).
The fact that, in our analysis, the beneﬁt-risk relationship
became less favorable with greater MAP reduction may be
important for patients and physicians, who aim for the
lowest cardiovascular risk with the lowest probability of
side effects (19–21). If this association is conﬁrmed by
prospective studies, future recommendations for hyper-
tension treatment in this population should consider
personalized targets (according to usual MAP) rather
than a ﬁxed cutoff for every patient.
In conclusion, MAP reduction .20 mm Hg in patients
with a target systolic BP ,120 mm Hg was associated with
higher incidence of kidney function decline. The beneﬁt-
risk balance of intensive treatment seemed to be less favorable
with greater MAP reduction. Prospective studies evaluating
the effect of MAP reduction in addition to hypertension
treatment target on kidney function decline and cardio-
vascular events are warranted.
Figure 4. | Therewas no significant heterogeneity by treatment group for the associationbetweenkidney function decline andcardiovascular
events of SPRINTparticipantswithout chronic kidney disease at baseline.Kidney function declinewas defined by$30% reduction in eGFR to
,60 ml/min per 1.73 m2 on two consecutive laboratory determinations collected at three-month time intervals. 95% CI, 95% confidence
interval.
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